Table 5.
Plasma TAC, MDA, adiponectin and hs-CRP of different experimental sub-groups.
| Group | TAC (mM/L) | MDA (nmole/ml) | Adiponectin (µg/ml) | hs-CRP (ng/L) |
|---|---|---|---|---|
| NC | 6.68a ± 0.2 | 5.27a ± 0.20 | 7.04a ± 0.11 | 107.9a ± 3.9 |
| MC | 3.49b ± 0.2 | 8.30b ± 0.07 | 3.36b ± 0.11 | 227.6b ± 24.2 |
| A | 4.49c ± 0.1 | 6.30cd ± 0.12 | 5.99c ± 0.11 | 120.9acd ± 1.8 |
| N1 | 4.54c ± 0.1 | 6.80ef ± 0.12 | 4.94d ± 0.08 | 129.4acd ± 2.2 |
| NN1 | 4.51c ± 0.1 | 6.60ce ± 0.11 | 4.98d ± 0.08 | 125.5acd ± 2.0 |
| N2 | 3.75b ± 0.2 | 7.20g ± 0.11 | 4.40e ± 0.13 | 129.9cd ± 2.3 |
| NN2 | 3.85b ± 0.1 | 6.90fg ± 0.07 | 4.70de ± 0.11 | 132.9d ± 1.8 |
| AN1 | 5.40d ± 0.2 | 5.70h ± 0.11 | 6.68f ± 0.10 | 111.1ac ± 3.2 |
| ANN1 | 5.20d ± 0.1 | 5.80h ± 0.11 | 6.56f ± 0.12 | 113.1acd ± 2.2 |
| AN2 | 4.49c ± 0.1 | 6.20d ± 0.11 | 5.90c ± 0.15 | 123.9acd ± 3.1 |
| ANN2 | 4.40c ± 0.1 | 6.00d ± 0.07 | 6.20c ± 0.13 | 123.3acd ± 1.6 |
Values are expressed as means ± SE (n = 8). Significance was considered at p < 0.05 within columns where different letters indicate statistical significance.
NC control normal, MC metabolic syndrome control, A rats given atorvastatin drug, N1 rats received nutraceutical 1, NN1 rats treated with nutraceutical 1nanostructure, N2 rats received nutraceutical 2, NN2 rats given nutraceutical 2 nanostructure, AN1 rats taken atorvastatin drug with nutraceutical 1, ANN1 rats given atorvastatin drug with nutraceutical 1 nanostructure, AN2 rats treated with atorvastatin drug with nutraceutical 2, ANN2 rats received atorvastatin drug with nutraceutical 2 nanostructure, TAC total antioxidant capacity, MDA malondialdehyde, hs-CRP high sensitivity C-reactive protein.